38 master-"https:" "https:" "https:" "https:" Fellowship research jobs at Northeastern University in United States
Sort by
Refine Your Search
-
bring their authentic selves to work, and achieve their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking
-
. To apply, visit https://northeastern.wd1.myworkdayjobs.com/en-US/careers/job/Boston-MA-Main-Campus/CSL-Seqirus-Medical-Affairs-Postdoctoral-Research-Fellow_R135293 Copyright 2025 Jobelephant.com Inc. All
-
, acquired, life-threatening blood disorder, and an approved therapy for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), two rare and serious kidney
-
. Describe your research and how it has contributed to your field? 2. What future directions do you anticipate for your research? 3. Who are your primary collaborators and what are your experiences with
-
change. To apply, visit https://northeastern.wd1.myworkdayjobs.com/en-US/careers/job/Boston-MA-Main-Campus/Scholar-Rock-Global-Scientific-Communications-Postdoctoral-Research-Fellow_R135770 Copyright 2025
-
employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will
-
to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive
-
Medical Communication strategy. Assist with the oversight of manuscript submission for RD disclosure review including manuscripts (primary and secondary), abstracts and posters for review and approval prior
-
to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive
-
disease, IgA nephropathy, primary membranous, nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global